MEDICLIN raises full-year guidance for the 2024 financial year – Biotech Investments

MEDICLIN AG / Key word(s): Forecast/Annual Results

MEDICLIN raises full-year guidance for the 2024 financial year

21-Jan-2025 / 16:36 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.


Offenburg, 21 January 2025

MEDICLIN raises full-year guidance for the 2024 financial year

MEDICLIN Aktiengesellschaft (Ticker: MED) announces that it is raising its guidance for the 2024 financial year.

Instead of a Group EBIT* between EUR 33.0 and 39.0 million, MEDICLIN now expects a Group EBIT between EUR 48.0 and 54.0 million. The sales forecast for the Group was raised from -2.0 % to 0.0 % to now 1.0 % to 3.0 %.

The preliminary figures for the fourth quarter and the 2024 financial year will be published on 27 February 2025.

* As defined on the company’s website at the following link

Contact for further information:
MEDICLIN Aktiengesellschaft
Okenstraße 27
77652 Offenburg

Ender Gülcan
Head of Investor Relations and Sustainability
Tel.: 0781/488-326
Fax: 0781/488-184
ender.guelcan@mediclin.de
www.mediclin.de
 

End of Inside Information


21-Jan-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this